
Sign up to save your podcasts
Or
In this episode, we sit down with Dr. Nicholas Ashton, senior director of Banner Research's Fluid Biomarker Program, to dive deep into the cutting-edge world of Alzheimer's biomarker research. We explore how advancements in diagnosing Alzheimer's without directly touching the brain are revolutionizing the field. Dr. Ashton breaks down the significance of clinical symptom analysis paired with innovative biological testing methods—ushering in a new era of Alzheimer's diagnosis. Breakthrough blood tests are creating new opportunities for earlier Alzheimer's detection, expanding beyond research to everyday clinical practices. We also discuss how these innovations are accelerating the recruitment process for clinical trials, speeding up the development of new treatments.
4.6
4949 ratings
In this episode, we sit down with Dr. Nicholas Ashton, senior director of Banner Research's Fluid Biomarker Program, to dive deep into the cutting-edge world of Alzheimer's biomarker research. We explore how advancements in diagnosing Alzheimer's without directly touching the brain are revolutionizing the field. Dr. Ashton breaks down the significance of clinical symptom analysis paired with innovative biological testing methods—ushering in a new era of Alzheimer's diagnosis. Breakthrough blood tests are creating new opportunities for earlier Alzheimer's detection, expanding beyond research to everyday clinical practices. We also discuss how these innovations are accelerating the recruitment process for clinical trials, speeding up the development of new treatments.
21,892 Listeners
12,599 Listeners
1,358 Listeners
3,476 Listeners
9,277 Listeners
147 Listeners
1,500 Listeners
18 Listeners
32 Listeners
3,318 Listeners
22 Listeners
41,393 Listeners
34 Listeners
168 Listeners
23 Listeners